Navigation Links
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Date:6/6/2009

ges and the light, discreet and easy to use AFRESA Inhaler. Administered at the start of a meal, AFRESA dissolves immediately upon inhalation and delivers insulin quickly to the blood stream. Peak insulin levels are achieved within 12 to 14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals. The AFRESA phase 2/3 clinical program included over 4,500 adult patients.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com, to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.

CONTACT: Alanna Jamieson, MCS Healthcare Public Relations, alannaj@mcspr.com, (908) 234-9900


'/>"/>
SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
2. PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
3. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
6. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
9. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
10. TNFerade(TM) Phase III Data Presented at ASCO
11. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Atossa Genetics, Inc. (NASDAQ: ATOS ... Kyle Guse , Chief Financial Officer & General Counsel, ... on Thursday, May 30, 2013, in New York ... The Company,s presentation is scheduled to begin at 3:30 ... To access the webcast, go to www.atossagenetics.com . ...
(Date:5/17/2013)... BEIJING , May 17, 2013 Sinovac Biotech ... vaccines in China , today announced that ... quarter ended March 31, 2013, before market on Tuesday, May ... Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, ... Company,s financial results and provide an update on recent corporate ...
(Date:5/16/2013)... CHICAGO, Ill. and MECHELEN, Belgium ... (Euronext: GLPG) and AbbVie (NYSE: ABBV ) ... collaboration to include Crohn,s disease.  Galapagos will fund and ... is designed to facilitate rapid progression into Phase 3.  ... 2015, AbbVie will pay Galapagos $50 million.  The terms ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... of the future is on display – and in use ... benefit hospitals and patients nationwide. Princeton HealthCare System ... to replace its downtown Princeton facility, has taken the extraordinary ... hospital,s proposed patient room in its existing hospital. ...
... Based on its recent analysis of the ... QRxPharma Limited with the 2010 North American Frost ... the Year for MoxDuo® immediate-release (IR) (Q8003IR) – ... of pain that also addresses some major challenges ...
Cached Medicine Technology:Hospital Room of the Future Debuts in New Jersey 2Hospital Room of the Future Debuts in New Jersey 3Hospital Room of the Future Debuts in New Jersey 4Frost & Sullivan Recognizes QRxPharma for Innovative Pain Relief Product MoxDuo 2Frost & Sullivan Recognizes QRxPharma for Innovative Pain Relief Product MoxDuo 3Frost & Sullivan Recognizes QRxPharma for Innovative Pain Relief Product MoxDuo 4
(Date:5/19/2013)... SUNDAY, May 19 (HealthDay News) -- Although spring arrived ... the summer allergy season will still be strong, according ... at Birmingham. Dr. Richard Waguespack, clinical professor in ... often results in a robust summer allergy season. However, ... as sneezing, wheezing and coughing, he added. "Tree ...
(Date:5/19/2013)... St. Louis, MO (PRWEB) May 19, 2013 ... Member Conference, May 19-22, 2013, at the Walt Disney ... the latest trends in supply chain innovation, care delivery ... a much different dynamic in all healthcare markets, ... necessary part of the conversation,” said Todd Ebert, Amerinet ...
(Date:5/19/2013)... May 19, 2013 Actos lawsuit ... litigation now underway in U.S. District Court, Western District ... dated May 3rd, the Court has modified the litigation’s ... eight cases rather than four. The next Status Conference ... May 23rd. (In re: Actos Product Liability Litigation, MDL ...
(Date:5/19/2013)... May 19, 2013 According to ... Analysis and Forecast (2013 – 2018): By Applications ... Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) ... image sensor market was $8.00 billion in 2012 ... 2018, at an estimated CAGR of 3.84% from ...
(Date:5/19/2013)... Fat Burning Furnace developed by Rob ... people with fat burning diet plans, training ... Burning Furnace package, people will receive the Fat Burning ... quickly. The Fat Burning Furnace manual includes fat loss ... muscle mass. In addition, this book covers step-by-step instructions, ...
Breaking Medicine News(10 mins):Health News:Managing Seasonal Allergies 2Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2
... 19 (HealthDay News) -- Scientists say they,ve identified the first ... known as plaque psoriasis. "We have searched for almost ... psoriasis," study senior author Anne Bowcock, professor of genetics at ... a university news release. "Individually, the rare mutations we have ...
... Brophy Marcus HealthDay Reporter , THURSDAY, April 19 ... may want to let it go. A new study suggests ... happier years later in life. Researchers from the University ... 60-somethings to see how it affected their emotional health. ...
... Australia have discovered that salicylate, the active ingredient in ... (AMP-activated protein kinase), a key player in regulating cell ... cellular fuel-gauge is switched on by exercise and the ... scientists at McMaster University, the University of Dundee and ...
... of pregnant women and newborns for the presence of ... according to a Vanderbilt study now available online and ... study,s senior author, Buddy Creech, M.D., MPH, assistant professor ... carrying MRSA may risk transmitting an infection to their ...
... HealthDay Reporter , THURSDAY, April 19 (HealthDay News) ... been diagnosed with early-onset Alzheimer,s disease, celebrated women,s basketball coach ... University of Tennessee Lady Vols team. "I,ve loved being ... recognize that the time has come to move into the ...
... , THURSDAY, April 19 (HealthDay News) -- Most people know ... cancer diagnosis low: Don,t smoke, eat healthy, exercise and get ... choices, and a new report suggests that lawmakers and private ... easier ones to make. ...
Cached Medicine News:Health News:Gene Behind Psoriasis Identified, Researchers Say 2Health News:'No Regrets' Outlook May Make for Sunnier Old Age 2Health News:'No Regrets' Outlook May Make for Sunnier Old Age 3Health News:McMaster researchers find potential for new uses of old drug 2Health News:Concerns about MRSA for expectant mothers may be unfounded 2Health News:Basketball Legend Pat Summitt Leaving as Tennessee Women's Coach 2Health News:Basketball Legend Pat Summitt Leaving as Tennessee Women's Coach 3Health News:Basketball Legend Pat Summitt Leaving as Tennessee Women's Coach 4Health News:Healthy Lifestyle Choices Could Cut Cancer Rates: Report 2Health News:Healthy Lifestyle Choices Could Cut Cancer Rates: Report 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: